An overview of conditioning regimens for haploidentical stem cell transplantation with post‐transplantation cyclophosphamide
- 29 April 2015
- journal article
- review article
- Published by Wiley in American Journal of Hematology
- Vol. 90 (6) , 541-548
Abstract
Haploidentical related donors are an attractive alternative source of stem cells for allogeneic stem cell transplantation due to widespread availability and ease of stem cell procurement. Historically, haploidentical stem cell transplantation (HaploSCT) with extensive T‐cell depletion has been associated with high rates of infectious complications and nonrelapse mortality (NRM). Post‐transplantation cyclophosphamide (PTCy) has been shown to induce immune tolerance, effectively control graft‐versus‐host‐disease (GVHD), and is associated with lower NRM, making it a preferred option for patients undergoing HaploSCT. Over the last decade, several groups investigated PTCy for GVHD prevention in HaploSCT; it is now successfully utilized with both myeloablative and nonmyeloablative conditioning regimens with survival comparable to HLA‐matched transplantation. Future directions will focus on optimizing conditioning regimens by diagnosis, improving donor selection, and enhancing graft‐versus‐leukemia effect. Am. J. Hematol. 90:541ȓ548, 2015.Keywords
This publication has 40 references indexed in Scilit:
- Concise Review: Umbilical Cord Blood Transplantation: Past, Present, and FutureStem Cells Translational Medicine, 2014
- HLA Match Likelihoods for Hematopoietic Stem-Cell Grafts in the U.S. RegistryNew England Journal of Medicine, 2014
- Design of a cost–effectiveness analysis alongside a randomized trial of transplantation using umbilical cord blood versus HLA-haploidentical related bone marrow in advanced hematologic cancerJournal of Comparative Effectiveness Research, 2014
- Depletion of T-cell receptor alpha/beta and CD19 positive cells from apheresis products with the CliniMACS deviceCytotherapy, 2013
- Negative depletion of α/β+ T cells and of CD19+ B lymphocytes: A novel frontier to optimize the effect of innate immunity in HLA-mismatched hematopoietic stem cell transplantationImmunology Letters, 2013
- Progress in Haploidentical Stem Cell TransplantationTransplantation and Cellular Therapy, 2012
- Current status of haploidentical stem cell transplantation for leukemiaJournal of Hematology & Oncology, 2008
- Unrelated Donor Hematopoietic Cell Transplantation: Factors Associated with a Better HLA MatchTransplantation and Cellular Therapy, 2008
- HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation CyclophosphamideTransplantation and Cellular Therapy, 2008
- Hematopoietic Stem-Cell TransplantationNew England Journal of Medicine, 2006